Citations

Showing 10 of 108081 citations.

Clinical presentation, hemorrhage risk, and outcome in patients with familial cavernous malformations: a pragmatic prospective analysis of 75 patients
Alalfi, Mohammed O. , Lanzino, Giuseppe , Flemming, Kelly D.

Mayo Clinic

Journal of Neurosurgery | March 17, 2023 | Volume: 139 | Issue: 4 | Pages: 1018-1024

10.3171/2023.1.jns222434 | PMID 36933254 Get It

OBJECTIVE Newly diagnosed patients with a familial cavernous malformation (FCM) and their families are concerned about their future outlook, which is scarcely discussed in the literature. The authors studied a prospective contemporary cohort of patients with FCMs to assess demographics, mode of presentation, prospective risk of hemorrhage and seizures, need for surgery, and functional outcome over an extended interval. METHODS A prospectively maintained database beginning January 1, 2015, of patients diagnosed with a cavernous malformation (CM) was queried. Data on demographics, radiological imaging, and symptoms at first diagnosis were collected in adult patients who gave their consent to prospective contact. Follow-up was done using questionnaires, in-person visits, and medical record review to assess for prospective symptomatic hemorrhage (i.e., the first hemorrhage after enrollment in the database), seizure, functional outcome measured by the modified Rankin Scale (mRS), and treatment. The prospective hemorrhage rate was calculated by the number of prospective hemorrhages divided by patient-years of follow-up censored at last follow-up, first prospective hemorrhage, or death. A Kaplan-Meier curve of survival free of hemorrhage was obtained comparing patients with versus without hemorrhage at the time of presentation and compared with a log-rank test for p < 0.05. RESULTS A total of 75 patients with FCM were included, of whom 60% were female. The mean age at diagnosis was 41 ± 16 years. Most symptomatic or large lesions were located supratentorially. At first diagnosis, 27 patients had no symptoms, and the remaining were symptomatic. Over an average of 9.9 years, the rate of prospective hemorrhage was 4.0% per patient-year, and the rate of new seizure was 1.2% per patient-year, with 64% and 32% of patients experiencing at least one symptomatic hemorrhage and at least one seizure, respectively. Thirty-eight percent of the patients underwent at least 1 surgery and 5.3% underwent stereotactic radiosurgery. At the last follow-up, 83.0% of patients remained independent with an mRS score ≤ 2. CONCLUSIONS The authors’ findings provide clinically useful information on hemorrhage rate, seizure rate, the likelihood of surgery, and functional outcome. These findings can be helpful to practicing physicians when counseling patients with FCM and their families, who are often apprehensive about their future and well-being.
Intraoperative diagnosis of facial schwannomas: a multicenter summation of clinical experience, preoperative avoidance, and intraoperative management protocol
Plitt, Aaron , Snyder, Lauren Rose, Hammerbeck-Ward, Charlotte , Neff, Brian A., Driscoll, Colin L. W., Carlson, Matthew L. , Lane, John I. , Lloyd, Simon , Freeman, Simon , Laitt, Roger, Abdulla, Sarah , Siripurapu, Rekha, Potter, Gillian , Link, Michael J., Rutherford, Scott , Plitt, Aaron R, Driscoll, Colin L., Lewis, Daniel , Hannan, Cathal John , Richardson, George E. , King, Andrew Thomas , Pathmanaban, Omar Nathan , Gompel, Jamie J. Van , Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | March 17, 2023 | Volume: 139 | Issue: 4 | Pages: 972-983

10.3171/2023.2.jns222368 | PMID 36933255 Get It

OBJECTIVE Preoperative differentiation of facial nerve schwannoma (FNS) from vestibular schwannoma (VS) can be challenging, and failure to differentiate between these two pathologies can result in potentially avoidable facial nerve injury. This study presents the combined experience of two high-volume centers in the management of intraoperatively diagnosed FNSs. The authors highlight clinical and imaging features that can distinguish FNS from VS and provide an algorithm to help manage intraoperatively diagnosed FNS. METHODS Operative records of 1484 presumed sporadic VS resections between January 2012 and December 2021 were reviewed, and patients with intraoperatively diagnosed FNSs were identified. Clinical data and preoperative imaging were retrospectively reviewed for features suggestive of FNS, and factors associated with good postoperative facial nerve function (House-Brackmann [HB] grade ≤ 2) were identified. A preoperative imaging protocol for suspected VS and recommendations for surgical decision-making following an intraoperative FNS diagnosis were created. RESULTS Nineteen patients (1.3%) with FNSs were identified. All patients had normal facial motor function preoperatively. In 12 patients (63%), preoperative imaging demonstrated no features suggestive of FNS, with the remainder showing subtle enhancement of the geniculate/labyrinthine facial segment, widening/erosion of the fallopian canal, or multiple tumor nodules in retrospect. Eleven (57.9%) of the 19 patients underwent a retrosigmoid craniotomy, and in the remaining patients, a translabyrinthine (n = 6) or transotic (n = 2) approach was used. Following FNS diagnosis, 6 (32%) of the tumors underwent gross-total resection (GTR) and cable nerve grafting, 6 (32%) underwent subtotal resection (STR) and bony decompression of the meatal facial nerve segment, and 7 (36%) underwent bony decompression only. All patients undergoing subtotal debulking or bony decompression exhibited normal postoperative facial function (HB grade I). At the last clinical follow-up, patients who underwent GTR with a facial nerve graft had HB grade III (3 of 6 patients) or IV facial function. Tumor recurrence/regrowth occurred in 3 patients (16%), all of whom had been treated with either bony decompression or STR. CONCLUSIONS Intraoperative diagnosis of an FNS during a presumed VS resection is rare, but its incidence can be reduced further by maintaining a high index of suspicion and undertaking further imaging in patients with atypical clinical or imaging features. If an intraoperative diagnosis does occur, conservative surgical management with bony decompression of the facial nerve only is recommended, unless there is significant mass effect on surrounding structures.
Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy
Marar, Rosalyn, Abbasi, Muhannad , Prathivadhi-Bhayankaram, Sruti , Daryanani, Andres , Villarraga, Hector R. , Anavekar, Nandan S., Bhatt, Vijaya Raj , Abbasi, Muhannad Aboud , Villarraga, Hector R , Paludo, Jonas , Bhatt, Vijaya Raj , Paludo, Jonas

Mayo Clinic

JCO Oncology Practice | March 17, 2023 | Volume: 19 | Issue: 6 | Pages: 331-342

10.1200/op.22.00713 | PMID 36930845 Get It

The field of malignant hematology is transforming with novel immunotherapeutic approaches. Unfortunately, quality of life, treatment efficacy, and life expectancy are negatively affected by cardiotoxic side effects of treatment. To date, the exact mechanism and incidence of cardiotoxicity associated with these therapies is unclear. These events are believed to be triggered or occur concurrently with cytokine release syndrome. Furthermore, there are no formal guidelines to provide evaluation, treatment, and surveillance. We aim to synthesize available literature with updates on the cardiotoxic effects of novel therapies used in malignant hematologic disorders, with a focus on chimeric antigen receptor T-cell therapy and bispecific T-cell engager therapy, along with a proposed algorithm that may guide pretreatment evaluation, monitoring during treatment, and post-treatment surveillance.
Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions
Lindström, Sara , Wang, Lu , Feng, Helian , Huo, Sijia , Harrison, Tabitha A. , Turman, Constance , Chen, Hongjie , Bammler, Theo K. , Gallinger, Steve, Gruber, Stephen B. , Moreno, Vı́ctor , Offit, Kenneth , O’Mara, Tracy A. , Tomlinson, Ian, Gharahkhani, Puya , MacGregor, Stuart , Schumacher, Johannes , Bondy, Melissa L. , Houlston, Richard S. , Jenkins, Robert B. , Melin, Beatrice , Wrensch, Margaret , Brennan, Paul , Johansson, Mattias , McKay, James , Aldrich, Melinda C. , Landi, Maria Teresa , Bishop, D. Timothy , Iles, Mark M. , Law, Matthew H. , Wolpin, Brian M. , Petersen, Gloria M. , Purdue, Mark P. , Scélo, Ghislaine , Kar, Siddhartha , Hung, Rayjean J, Kraft, Peter , Lissowska, Jolanta , Simard, Jacques , Dörk, Thilo , John, Esther M. , Carracedo, Ángel , Huang, Wen‐Yi , Vodička, Pavel , Taylor, Jack A. , Lessel, Davor , Kurian, Allison W. , Hung, Rayjean J. , Kundaje, Anshul , Zhong, Jun , Turman, Constance , Chen, Hongjie , Gruber, Stephen B , Marchand, Loïc Le , Moreno, Victor , Offit, Kenneth , Gharahkhani, Puya , MacGregor, Stuart , Schumacher, Johannes , Houlston, Richard S , Brennan, Paul , Johansson, Mattias , Iles, Mark M , Law, Matthew H , Amundadottir, Laufey , Klein, Alison P , Petersen, Gloria, Chanock, Stephen Jacob , Kar, Siddhartha , Kraft, Peter , Dörk, Thilo , Lissowska, Jolanta , John, Esther M , Hung, Rayjean J , Harrison, Tabitha A , O'Mara, Tracy A , Lessel, Davor , Bishop, D Timothy , Huang, Wen-Yi , Taylor, Jack A , Simard, Jacques , Kurian, Allison W , Kundaje, Anshul , Vodicka, Pavel , Zhong, Jun , Majumdar, Arunabha , MacDonald, James W. , Mancuso, Nicholas , Gunter, Marc J. , Marchand, Loı̈c Le , Vivo, Immaculata De , Spurdle, Amanda B. , Fitzgerald, Rebecca C. , Gockel, Ines , Jankowski, Janusz , Barnholtz‐Sloan, Jill S. , Christiani, David C. , Amos, Christopher I. , Tardón, Adonina , Démenais, Florence , Goldstein, Alisa M. , Kanetsky, Peter A. , Ámundadóttir, Laufey T. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Risch, Harvey A. , Pharoah, Paul D.P. , Paşaniuc, Bogdan

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 17, 2023 | Volume: 115 | Issue: 6 | Pages: 712-732

10.1093/jnci/djad043 | PMID 36929942 Get It

Abstract Background The shared inherited genetic contribution to risk of different cancers is not fully known. In this study, we leverage results from 12 cancer genome-wide association studies (GWAS) to quantify pairwise genome-wide genetic correlations across cancers and identify novel cancer susceptibility loci. Methods We collected GWAS summary statistics for 12 solid cancers based on 376 759 participants with cancer and 532 864 participants without cancer of European ancestry. The included cancer types were breast, colorectal, endometrial, esophageal, glioma, head and neck, lung, melanoma, ovarian, pancreatic, prostate, and renal cancers. We conducted cross-cancer GWAS and transcriptome-wide association studies to discover novel cancer susceptibility loci. Finally, we assessed the extent of variant-specific pleiotropy among cancers at known and newly identified cancer susceptibility loci. Results We observed widespread but modest genome-wide genetic correlations across cancers. In cross-cancer GWAS and transcriptome-wide association studies, we identified 15 novel cancer susceptibility loci. Additionally, we identified multiple variants at 77 distinct loci with strong evidence of being associated with at least 2 cancer types by testing for pleiotropy at known cancer susceptibility loci. Conclusions Overall, these results suggest that some genetic risk variants are shared among cancers, though much of cancer heritability is cancer-specific and thus tissue-specific. The increase in statistical power associated with larger sample sizes in cross-disease analysis allows for the identification of novel susceptibility regions. Future studies incorporating data on multiple cancer types are likely to identify additional regions associated with the risk of multiple cancer types.
Adverse events following COVID‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia
Yasmin, Farah , Najeeb, Hala , Naeem, Unaiza , Moeed, Abdul , Atif, Abdul Raafe , Asghar, Muhammad Sohaib , Nimri, Nayef , Saleem, Maryam , Krittanawong, Chayakrit , Eljack, Mohammed Mahmmoud Fadelallah , Tahir, Muhammad Junaid, Waqar, Fahad , Mahmmoud Fadelallah Eljack, Mohammed , Asghar, Muhammad S , Bandyopadhyay, Dhrubajyoti , Krittanawong, Chayakrit

Mayo Clinic

Immunity, Inflammation and Disease | March 17, 2023 | Volume: 11 | Issue: 3 | Pages: No page available

10.1002/iid3.807 | PMID 36988252 Get It

AbstractBackground and ObjectivesSince publishing successful clinical trial results of mRNA coronavirus disease 2019 (COVID‐19) vaccines in December 2020, multiple reports have arisen about cardiovascular complications following the mRNA vaccination. This study provides an in‐depth account of various cardiovascular adverse events reported after the mRNA vaccines' first or second dose including pericarditis/myopericarditis, myocarditis, hypotension, hypertension, arrhythmia, cardiogenic shock, stroke, myocardial infarction/STEMI, intracranial hemorrhage, thrombosis (deep vein thrombosis, cerebral venous thrombosis, arterial or venous thrombotic events, portal vein thrombosis, coronary thrombosis, microvascular small bowel thrombosis), and pulmonary embolism.MethodsA systematic review of original studies reporting confirmed cardiovascular manifestations post‐mRNA COVID‐19 vaccination was performed. Following the PRISMA guidelines, electronic databases (PubMed, PMC NCBI, and Cochrane Library) were searched until January 2022. Baseline characteristics of patients and disease outcomes were extracted from relevant studies.ResultsA total of 81 articles analyzed confirmed cardiovascular complications post‐COVID‐19 mRNA vaccines in 17,636 individuals and reported 284 deaths with any mRNA vaccine. Of 17,636 cardiovascular events with any mRNA vaccine, 17,192 were observed with the BNT162b2 (Pfizer−BioNTech) vaccine, 444 events with mRNA‐1273 (Moderna). Thrombosis was frequently reported with any mRNA vaccine (n = 13,936), followed by stroke (n = 758), myocarditis (n = 511), myocardial infarction (n = 377), pulmonary embolism (n = 301), and arrhythmia (n = 254). Stratifying the results by vaccine type showed that thrombosis (80.8%) was common in the BNT162b2 cohort, while stroke (39.9%) was common with mRNA‐1273 for any dose. The time between the vaccination dosage and the first symptom onset averaged 5.6 and 4.8 days with the mRNA‐1273 vaccine and BNT162b2, respectively. The mRNA‐1273 cohort reported 56 deaths compared to the 228 with BNT162b2, while the rest were discharged or transferred to the ICU.ConclusionAvailable literature includes more studies with the BNT162b2 vaccine than mRNA‐1273. Future studies must report mortality and adverse cardiovascular events by vaccine types.
Is baclofen the least worst option for spasticity management in children?
Brandenburg, Joline E.

Mayo Clinic

Journal of Pediatric Rehabilitation Medicine | March 17, 2023 | Volume: 16 | Issue: 1 | Pages: 11-17

10.3233/prm-230001 | PMID 36938744 Get It

Baclofen is often considered a first-line treatment option for spasticity management in children. However, adverse effects, administration, and dosing can be barriers to effectiveness. In my practice, other medications for spasticity management are often used prior to initiating baclofen. In this article, baclofen use for spasticity management in children is briefly reviewed along with discussion of approaches using other medications as first-line treatment options. I will present a rationale for medication selection for spasticity management and discuss the approaches I take in medication selection that incorporate spasticity severity, patient goals, and medication side effect profiles.
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study
Fazio, Nicola , Gervaso, Lorenzo , Hálfdánarson, Þorvarður R. , Eiring, Rachel A. , Stocchetti, Benedetta Lombardi , Grozinsky‐Glasberg, Simona , Gross, David J. , Walter, Thomas , Robelin, Patrick, Bagnardi, Vincenzo , Antonuzzo, Lorenzo , Sparano, Clotilde , Gelsomino, Fabio, Rossi, Maura , Cives, Mauro , Kakil, I. R., Hamid, Hytam, Squadroni, M., Koumarianou, Anna, Boselli, S., Tamayo, Darina, Mazzon, Cristina, Rubino, Manila , Spada, Francesca , Sonbol, Mohamad, Grozinsky-Glasberg, Simona , Sparano, Clotilde , Massironi, Sara , Hofland, Johannes , Halfdanarson, Thorvardur R , Eiring, Rachel A , Antonuzzo, Lorenzo , Sonbol, Mohamad Bassam , Pusceddu, Sara , Prinzi, Natalie , Lombard‐Bohas, Catherine , Frassoni, Samuele , Gelsomino, Fabio , Bongiovanni, Alberto , Ranallo, Nicoletta , Tafuto, Salvatore , Chirco, Alessandra, Salvia, Anna La , Hernando, Jorge , Hofland, Johannes

Mayo Clinic

Endocrine-Related Cancer | March 17, 2023 | Volume: 30 | Issue: 6 | Pages: No page available

10.1530/erc-22-0395 | PMID 36930250 Get It

We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis.Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.
Case Studies in Physiology: Male to female transgender swimmer in college athletics
Senefeld, Jonathon W. , Hunter, Sandra K. , Coleman, Doriane Lambelet, Joyner, Michael J. , Hunter, Sandra K , Joyner, Michael J , Senefeld, Jonathon W

Mayo Clinic

Journal of Applied Physiology | March 17, 2023 | Volume: 134 | Issue: 4 | Pages: 1032-1037

10.1152/japplphysiol.00751.2022 | PMID 36927141 Get It

This case study, longitudinal analysis of freestyle swimming performances before and after 2 yr of feminizing gender-affirming hormone therapy of an elite transgender woman (male sex, female gender identity), demonstrates superior performance relative to rank-matched female swimmers and a lower performance gap than previously observed between elite male and female swimmers.
Sonolucent Cranioplasty in Extracranial to Intracranial Bypass Surgery: Early Multicenter Experience of 44 Cases
Salem, Mohamed M , Ravindran, Krishnan , Hoang, Alex Nguyen , Doron, Omer , Esparza, Rogelio , Raper, Daniel , Jankowitz, Brian T. , Tanweer, Omar , Langer, David J. , Nossek, Erez , Burkhardt, Jan‐Karl , Burkhardt, Jan‐Karl , Lopes, Demetrius K.

Mayo Clinic

Operative Neurosurgery | March 17, 2023 | Volume: 25 | Issue: 1 | Pages: 20-27

10.1227/ons.0000000000000674 | PMID 36929760 Get It

BACKGROUND: The new sonolucent cranioplasty implant (clear polymethyl methacrylate, PMMA) adds functionality besides surgical reconstruction. One possible application uses the transcranioplasty ultrasound (TCUS) technique after PMMA cranioplasty to assess graft patency of extracranial-intracranial (EC-IC) bypass procedures. OBJECTIVE: To report our early multicenter experience. METHODS: This is a multicenter analysis of consecutive EC-IC bypass patients from 5 US centers (2019-2022) with closure postbypass using PMMA implant. RESULTS: Forty-four patients (median age 53 years, 68.2% females) were included. The most common indication for bypass was Moyamoya disease/syndrome (77.3%), and superficial temporal artery to middle cerebral artery bypass was the most common procedure (79.5%). Pretreatment modified Rankin Scales of 0 and 1 to 2 were noted in 11.4% and 59.1% of patients, respectively. Intraoperative imaging for bypass patency involved a combination of modalities; Doppler was the most used modality (90.9%) followed by indocyanine green and catheter angiography (86.4% and 61.4%, respectively). Qualitative TCUS assessment of graft patency was feasible in all cases. Postoperative inpatient TCUS confirmation of bypass patency was recorded in 56.8% of the cases, and outpatient TCUS surveillance was recorded in 47.7%. There were no cases of bypass failure necessitating retreatment. Similarly, no implant-related complications were encountered in the cohort. Major complications requiring additional surgery occurred in 2 patients (4.6%) including epidural hematoma requiring evacuation (2.3%) and postoperative surgical site infection (2.3%) that was believed to be unrelated to the implant. CONCLUSION: This multicenter study supports safety and feasibility of using sonolucent PMMA implant in EC-IC bypass surgery with the goal of monitoring bypass patency using TCUS.